Invasive procedures to biopsy tissue from cancer-tainted organs could be replaced by simply taking samples from a tiny “decoy” implanted just beneath the skin, University of Michigan researchers have demonstrated in mice.
These devices have a knack for attracting cancer cells traveling through the body. In fact, they can even pick up signs that cancer is preparing to spread, before cancer cells arrive.
“Biopsying an organ like the lung is a risky procedure that’s done only sparingly,” said Lonnie Shea, the William and Valerie Hall Chair of biomedical engineering at U-M. “We place these scaffolds right under the skin, so they’re readily accessible.”
The ease of access would also allow doctors to monitor the effectiveness of cancer treatments closer to real time.
The U-M team’s most recent work appears in Cancer Research, a publication of the American Association for Cancer Research.
Biopsies of the scaffold allowed researchers to analyze 635 genes present in the captured cancer cells. From these genes, the team identified ten that could predict whether a mouse was healthy, if it had a cancer that had not begun to spread yet, or if a cancer was present and had begun to spread. They could do that all without the need for an invasive biopsy of an organ.
The gene expression obtained at the scaffold had distinct patterns relative to cells from the blood, which are obtained through a technique known as liquid biopsy. These differences highlight that the tissue in these traps provides unique information that correlates with disease progression.
The researchers have demonstrated that the synthetic scaffolds work with multiple types of cancers in mice, including pancreatic cancer. They work by luring immune cells, which, in turn, attract cancer cells.
“When we started off, the idea was that we would biopsy the scaffold and look for tumor cells that had followed the immune cells there,” Shea said. “But we realized that by analyzing the immune cells that gather first, we can detect the cancer before it’s spreading.”
In treating cancer, early detection is key.
“Currently, early signs of metastasis can be difficult to detect,” said Jacqueline Jeruss, an associate professor of surgery and biomedical engineering and a co-author of the study. “Imaging may be done once a patient experiences symptoms, but that implies the number of cancer cells may already be substantial. Improved detection methods are needed to identify metastasis at a point when targeted treatments can have a significant beneficial impact on slowing disease progression.”
The immune cells allowed researchers to identify whether treatments were effective in the mice and which subjects were sensitive or resistant to treatment.
The decoy’s ability to draw immune and cancer cells can also bolster the treatment itself. In previous research, the devices demonstrated an ability to slow the growth of metastatic breast cancer tumors in mice, by reducing the number of cancer cells that can reach those tumors.
In the future, Shea envisions that the scaffolds could be outfitted with sensors and Bluetooth technology that could deliver information in real time without the need for a biopsy.
Learn more: Implantable cancer traps could provide earlier diagnosis, help monitor treatment
The Latest on: Biopsies
[google_news title=”” keyword=”biopsies” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Biopsies
- OncoHost on liquid biopsy, AI, and developing Israel’s life sciences ecosystemon May 17, 2024 at 1:49 pm
Liquid biopsy technology is advancing, but investors remain sceptical. Startups across Israel are developing liquid biopsy tests, and the quest for investment is growing ever more competitive. As a ...
- Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsieson May 16, 2024 at 5:05 pm
The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercializat ...
- Intense ultrasound enables less invasive cancer biopsieson May 16, 2024 at 5:00 pm
This information requires invasive biopsies, which can be damaging. Now, a team of researchers from the University of Alberta (Canada) has developed a technique to extract this information in a less ...
- New test could avoid unnecessary biopsieson May 16, 2024 at 9:09 am
A new urine test for prostate cancer could help some men with high prostate-specific antigen numbers avoid unnecessary scans and biopsies. The FOX Medical Team's Beth Galvin talked with the doctor who ...
- New urine test may help men with elevated PSA levels avoid unnecessary biopsieson May 16, 2024 at 8:36 am
A new urine test could help men with an elevated PSA, or prostate specific antigen, level avoid unnecessary biopsies and MRIs. The test screens for 18 genetic markers in the urine that are highly ...
- Higher Risk Breast Cancer Screening: Which Test to Use?on May 15, 2024 at 6:30 am
Decisions about who can benefit from additional screening and what screening modality is most appropriate are complex.
- Exploring how intense ultrasound can release biological indicators of diseaseon May 14, 2024 at 7:34 am
Ultrasound imaging offers a valuable and noninvasive way to find and monitor cancerous tumors. However, much of the most crucial information about a cancer, such as specific cell types and mutations, ...
- NCH Health: New tech for lung biopsies for earlier cancer detectionon May 13, 2024 at 2:28 am
In our commitment to advancing patient care, I am thrilled to introduce the latest breakthrough in lung biopsy technology.
- Prostate Cancer Breakthrough: Urine Test Avoids Unnecessary Biopsieson April 28, 2024 at 9:57 pm
A study in JAMA Oncology reveals that MyProstateScore 2.0, a new urine test analyzing 18 genes, surpasses PSA in detecting significant prostate cancers and could reduce unnecessary biopsies by up to ...
- New Urine Test for Prostate Cancer May Help Reduce Unnecessary Biopsieson April 21, 2024 at 5:00 pm
The test also significantly reduced unnecessary biopsies for individuals with indolent, low-grade prostate cancer. The results are exciting, but questions remain as to whether the test would ...
via Bing News